Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Telithromycin, first ketolide].

Y Van Laethem1, J Sternon

  • 1Service des Maladies Infectieuses, C.H.U. Saint-Pierre, U.L.B.

Revue Medicale De Bruxelles
|April 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reactivation of Plasmodium infection during a treatment with infliximab: A case report.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2019
Same author

Revue medicale de Bruxelles·2017
Same author

Traitement Des Infections Bronchopulmonaires Aigues Par Le Laurylsulfate De Tetracycline Intra-Musculaire.

Acta clinica Belgica·2016
Same author

A rare case of hematemesis following gastro-duodenal strongyloides infection.

Acta gastro-enterologica Belgica·2015
Same author

[Do we have to vaccinate children against influenza?].

Revue medicale de Bruxelles·2015
Same author

Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009-2011.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2014
Same journal

[Breast cancer screening : a tool for informed decision making].

Revue medicale de Bruxelles·2018
Same journal

[Breast cancer screening : present situation and prospects].

Revue medicale de Bruxelles·2018
Same journal

[Guidelines in medical imaging : objectives, limits and radiation protection].

Revue medicale de Bruxelles·2018
Same journal

[How to avoid overmedicalization of the elderly patient ?]

Revue medicale de Bruxelles·2018
Same journal

[Ethical, pedagogical, socio-political and anthropological implications of quaternary prevention].

Revue medicale de Bruxelles·2018
Same journal

[New strategies in specific care for benign prostatic hypertrophy in older men].

Revue medicale de Bruxelles·2018
See all related articles

Telithromycin, a novel ketolide antibiotic, effectively treats common bacterial infections, including those resistant to penicillin and macrolides. However, potential drug interactions and resistance development require careful consideration.

Area of Science:

  • Pharmacology and Microbiology
  • Antibiotic Resistance
  • Infectious Diseases

Background:

  • Emergence of bacterial resistance to existing antibiotics like penicillin and macrolides necessitates novel therapeutic agents.
  • Telithromycin is the first marketed ketolide antibiotic, offering a new class of antimicrobials.

Purpose of the Study:

  • To evaluate the efficacy of Telithromycin as an alternative treatment for community-acquired pneumonia and other bacterial infections.
  • To assess Telithromycin's activity against common respiratory pathogens, including penicillin- and macrolide-resistant strains.

Main Methods:

  • Analysis of Telithromycin's mechanism of action, focusing on its dual binding sites on the bacterial ribosome.
  • Review of clinical data and in vitro studies demonstrating Telithromycin's spectrum of activity.

Related Experiment Videos

Main Results:

  • Telithromycin exhibits potent activity against a majority of penicillin- and macrolide-resistant bacteria, including Streptococcus pneumoniae and Streptococcus pyogenes.
  • Demonstrated efficacy in treating community-acquired pneumonia, bacterial pharyngoamygdalitis, suppurative sinusitis, and bronchitis.

Conclusions:

  • Telithromycin presents a viable alternative to beta-lactams and moxifloxacin for specific bacterial infections.
  • Potential challenges include drug interactions and the risk of antimicrobial resistance development, warranting cautious clinical use.